Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study
Stacy W Gray, Elyse R Park, Julie Najita, Yolanda Martins, Lara Traeger, Elizabeth Bair, Joshua Gagne, Judy Garber, Pasi A Jänne, Neal Lindeman, Carol Lowenstein, Nelly Oliver, Lynette Sholl, Eliezer M Van Allen, Nikhil Wagle, Sam Wood, Levi Garraway, Steven Joffe, Stacy W Gray, Elyse R Park, Julie Najita, Yolanda Martins, Lara Traeger, Elizabeth Bair, Joshua Gagne, Judy Garber, Pasi A Jänne, Neal Lindeman, Carol Lowenstein, Nelly Oliver, Lynette Sholl, Eliezer M Van Allen, Nikhil Wagle, Sam Wood, Levi Garraway, Steven Joffe
Abstract
Purpose: Although targeted sequencing improves outcomes for many cancer patients, it remains uncertain how somatic and germ-line whole-exome sequencing (WES) will integrate into care.
Methods: We conducted surveys and interviews within a study of WES integration at an academic center to determine oncologists' attitudes about WES and to identify lung and colorectal cancer patients' preferences for learning WES findings.
Results: One-hundred sixty-seven patients (85% white, 58% female, mean age 60) and 27 oncologists (22% female) participated. Although oncologists had extensive experience ordering somatic tests (median 100/year), they had little experience ordering germ-line tests. Oncologists intended to disclose most WES results to patients but anticipated numerous challenges in using WES. Patients had moderately low levels of genetic knowledge (mean 4 correct out of 7). Most patients chose to learn results that could help select a clinical trial, pharmacogenetic and positive prognostic results, and results suggesting inherited predisposition to cancer and treatable noncancer conditions (all ≥95%). Fewer chose to receive negative prognostic results (84%) and results suggesting predisposition to untreatable noncancer conditions (85%).
Conclusion: The majority of patients want most cancer-related and incidental WES results. Patients' low levels of genetic knowledge and oncologists' inexperience with large-scale sequencing present challenges to implementing paired WES in practice.Genet Med 18 10, 1011-1019.
Trial registration: ClinicalTrials.gov NCT02127359.
Figures
References
- Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565–574. doi: 10.1038/gim.2013.73.
- Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol. 2015 Aug; doi: 10.1200/JCO.2015.63.0996. JCO.2015.63.0996.
- Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609–1615.
- Domchek SM. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality. JAMA. 2010;304(9):967. doi: 10.1001/jama.2010.1237.
- Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003;349(16):1517–1525. doi: 10.1056/NEJMoa012915.
- Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118(5):829–834. doi: 10.1016/S0016-5085(00)70168-5.
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672. doi: 10.1056/NEJMoa052306.
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037. doi: 10.1056/NEJM200104053441401.
- Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–819. doi: 10.1056/NEJMoa1002011.
- Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi: 10.1056/NEJMoa0810699.
- MacConaill LE, Garcia E, Shivdasani P, et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn. 2014;16(6):660–672. doi: 10.1016/j.jmoldx.2014.06.004.
- Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015;17(3):251–264. doi: 10.1016/j.jmoldx.2014.12.006.
- Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. J Clin Oncol. 2013;31(15):1825–1833. doi: 10.1200/JCO.2013.48.7215.
- Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Science Translational Medicine. 2011;3(111):111ra121–111ra121. doi: 10.1126/scitranslmed.3003161.
- Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Cancer genomics and inherited risk. J Clin Oncol. 2014;32(7):687–698. doi: 10.1200/JCO.2013.49.7271.
- Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014;32(13):1317–1323. doi: 10.1200/JCO.2013.52.4298.
- Nippert I, Harris HJ, Julian-Reynier C, et al. Confidence of primary care physicians in their ability to carry out basic medical genetic tasks—a European survey in five countries—Part 1. J Community Genet. 2010;2(1):1–11. doi: 10.1007/s12687-010-0030-0.
- Michie S, di Lorenzo E, Lane R, Armstrong K, Sanderson S. Genetic information leaflets: Influencing attitudes towards genetic testing. Genet Med. 2004;6(4):219–225. doi: 10.1097/01.GIM.0000132685.60259.EA.
- Sanderson SC. The effects of a genetic information leaflet on public attitudes towards genetic testing. Public Understanding of Science. 2005;14(2):213–224. doi: 10.1177/0963662505050993.
- Singer E, Antonucci T, Van Hoewyk J. Racial and ethnic variations in knowledge and attitudes about genetic testing. Genet Test. 2004;8(1):31–43. doi: 10.1089/109065704323016012.
- Furr LA, Kelly SE. The Genetic Knowledge Index: developing a standard measure of genetic knowledge. Genet Test. 1999;3(2):193–199.
- Fagerlin A, Zikmund-Fisher BJ, Ubel PA, Jankovic A, Derry HA, Smith DM. Measuring numeracy without a math test: development of the Subjective Numeracy Scale. Med Decis Making. 2007;27(5):672–680. doi: 10.1177/0272989X07304449.
- Chew LD, Griffin JM, Partin MR, et al. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med. 2008;23(5):561–566. doi: 10.1007/s11606-008-0520-5.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655.
- Basch E, Artz D, Dulko D, et al. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol. 2005;23(15):3552–3561. doi: 10.1200/JCO.2005.04.275.
- Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
- Apex CoVantage LLC. Degner_info needs decisional preferences women breast cancer_JAMA_1997. 2008 Jul;:1–8.
- Zou G. A modified poisson regression approach to prospective studies with binary data. American Journal of Epidemiology. 2004;159(7):702–706. doi: 10.1093/aje/kwh090.
- NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®)Non-Small Cell LungCancer. [Accessed February 1, 2014]; Version . . Published January 24, 2014.
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer Version 2.2015. J Natl Compr Canc Netw. 2014 Oct;:1–143. .
- Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20(6):682–688. doi: 10.1038/nm.3559.
- Ramoni RB, McGuire AL, Robinson JO, Morley DS, Plon SE, Joffe S. Experiences and attitudes of genome investigators regarding return of individual genetic test results. Genet Med. 2013;15(11):882–887. doi: 10.1038/gim.2013.58.
- Sheehan M. The right to know and genetic testing. Journal of Medical Ethics. 2015;41(4):287–288. doi: 10.1136/medethics-2015-102767.
- Johnson JA. Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics. 2013;14(7):835–843. doi: 10.2217/pgs.13.52.
- Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet Med. 2011;13(12):987–995. doi: 10.1097/GIM.0b013e318238b38c.
- Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing. Clin Pharmacol Ther. 2011;89(3):387–391. doi: 10.1038/clpt.2010.320.
- Center for Drug Evaluation, Research. Genomics - Table of Pharmacogenomic Biomarkers in Drug Labeling. [Accessed January 23, 2015]; .
- Parsons DW, Roy A, Plon SE, Roychowdhury S, Chinnaiyan AM. Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. J Clin Oncol. 2014;32(21):2203–2205. doi: 10.1200/JCO.2013.54.8917.
- Parker BA, Schwaederle M, Scur MD, et al. J Oncol Pract. University of California, San Diego; Moores Cancer Center: Aug, 2015. Breast Cancer Experience of the Molecular Tumor Board at the.
- Green MJ, Peterson SK, Baker MW, et al. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility. JAMA. 2004;292(4):442–452.
- Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol. 2010;28(5):893–901. doi: 10.1200/JCO.2009.27.0660.
Source: PubMed